We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Plasma Energy Drives Innovative Tissue Dissection System

By HospiMedica International staff writers
Posted on 04 Aug 2009
A family of disposable low-temperature surgical cutting and coagulation devices possesses the precise control of a scalpel and the bleeding control of traditional electrosurgery, without causing extensive collateral damage. More...


The PlasmaBlade family of devices includes the PlasmaBlade 4.0, which is designed to be used to cut through all types of soft tissue, including skin, fat and muscle; the PlasmaBlade Needle, which has a fine needlepoint tip and is specifically designed for ultraprecise surgical procedures; and the PlasmaBlade EXT, which is designed for use in surgical procedures requiring an extended-reach tip. The source of the radiofrequency (RF) energy used with the devices is supplied by the PULSAR Generator, which produces the pulsed plasma RF energy required by the PlasmaBlade to incise tissue and control bleeding. Because the RF energy is provided through short on-and-off pulses via a highly insulated cutting electrode, the PlasmaBlade cuts at half the average temperature of a conventional electrosurgery device, and can be as low as 50 ºC, resulting in significantly less damage to surrounding tissues compared to traditional electrosurgery. The PlasmaBlade is also able to dissect tissue in both a dry or completely submerged surgical field, another shortcoming of traditional electrosurgical devices. Other benefits include effective bleeding control, minimal thermal tissue injury, reduced scarring and inflammation, and improved surgical incision healing and strength. The PlasmaBlade and PULSAR Generator are part of the PEAK Surgery System, developed by PEAK Surgical (Palo Alto, CA, USA), and have been approved by both the U.S. Food and Drug Administration (FDA) and the European Community (CE Marking).

"The PlasmaBlades worked beautifully in the partial laryngectomy and parotid dissection we conducted, producing nearly bloodless procedures,” said Raul Pellini, M.D., an ear, nose, and throat (ENT) surgeon at Istituti Fisioterapici Ospitalieri (Rome, Italy), who was the first to use the system in Europe. "We are very keen for our ENT colleagues to evaluate these innovative devices as we expect that their patients will experience similar positive outcomes.”
The PEAK pulsed plasma-mediated discharges and electrode insulation techniques were originally invented at the Hansen experimental physics laboratory and the department of ophthalmology at Stanford University (CA, USA).

Related Links:
PEAK Surgical
Stanford University
Istituti Fisioterapici Ospitalieri



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Electrode Solution and Skin Prep
Signaspray
Exam Table
PF400
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.